Cumberland Pharmaceuticals is a small specialty pharma company that acquires, develops, and commercializes branded prescription drugs in three markets: hospital acute care, gastroenterology, and oncology. Cumberland's core business model centers on acquiring FDA-approved or late-stage branded drugs and commercializing them through a lean sales force of roughly 60 professionals targeting concentrated prescriber bases. Cumberland's four primary commercial products are Vibativ (IV antibiotic for drug-resistant gram-positive infections including MRSA), Sancuso (the only FDA-approved transdermal patch for chemotherapy-induced nausea), Kristalose (a branded crystalline prescription laxative in pre-measured packets), and Caldolor (the first and only injectable ibuprofen approved in the U.S. for pain and fever, including in infants). Cumberland also markets Acetadote (IV acetylcysteine for acetaminophen overdose) and, as of 2025, Talicia (a fixed-dose oral combination for H. pylori infection, via a joint venture with RedHill Biopharma). Cumberland sells primarily through three U.S. wholesale distributors and licenses products internationally to local partners who handle commercialization. Beyond its commercial portfolio, Cumberland is advancing ifetroban, a thromboxane receptor antagonist in Phase II trials for Duchenne muscular dystrophy cardiomyopathy, systemic sclerosis, and idiopathic pulmonary fibrosis — with DMD representing the lead and potentially most significant opportunity given its Orphan Drug designation and the absence of any approved cardiac therapy for DMD patients.